-
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
Topline data expected in 4Q2021 SIOUX FALLS, S.D., September 15, 2021 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a…
-
SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences
SIOUX FALLS, S.D., September 8, 2021 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that…
-
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
FDA findings from research published in bioRxiv using in vitro pseudovirus models confirm SAB-185 broadly neutralizes variants of concern SAB-185…
-
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
Click here for webcast July 09, 2021 07:00 AM Eastern Daylight Time SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage…
-
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
Findings Published in Human Vaccines & Immunotherapeutics Show SAB-185 Neutralizes Virus Strains Containing Substitutions Present in Variants of Concern…
-
Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics
NEWS PROVIDED BY Big Cypress Acquisition Corp. Jul 07, 2021, 07:00 ET MIAMI, July 7, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP),…
-
SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
First High-Potency Human Polyclonal Antibody Therapeutic Specifically Designed with the Potential to Treat Rapidly-Mutating Type A and Type B Influenza…
-
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp.
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated…
-
SAB Biotherapeutics to Participate in Expert Panel at BIO Digital 2021
SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that…
-
SAB Biotherapeutics Appoints Carlos Carrillo, PhD, as Senior Vice President, Regulatory Affairs
SIOUX FALLS, S.D., June 10, 2021–SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to…
-
SAB Biotherapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
May 13, 2021 09:52AM CENTRAL STANDARD TIME Sioux Falls, SD-(BUSINESS WIRE)-SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company…
-
SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
Part of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2) master protocol Trials are funded, sponsored and conducted by…